Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | MGAM | O43451 | 1/20 | 0.52 |
| ▸ | SI | P14410 | 1/20 | 0.52 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13095918 | 0.91 | GAA (0.44) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL13095858 | 0.84 | CYP1A2 (0.48) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL20931319 | 0.82 | GAA (0.56) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL8413025 | 0.82 | GAA (0.55) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL16809402 | 0.81 | KMT2A (0.50) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL10499002 | 0.81 | NAAA (0.39) | GAAKMT2AALDH1A1LMNANPSR1 | |
| SCHEMBL8682815 | 0.81 | GAA (0.48) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL47545 | 0.80 | GAA (0.52) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL11220004 | 0.80 | GAA (0.52) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL11361701 | 0.80 | GAA (0.52) | GAAMGAMSIMGAM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4541830-A1 | PROCESS FOR PRODUCING POLYURETHANE FOAM | Covestro Deutschland AG (DE) | 2025-04-23 | — | — | EP | claimed |
| CN-118562037-A | Reactive water-soluble polymer, adhesive and application | 上海佰奥聚新材料科技有限公司 | 2024-08-30 | — | — | CN | claimed |
| CN-115745707-A | Organic fertilizer prepared from fruit and vegetable wastes and preparation method of organic fertilizer | 山东新阡陌农业发展有限公司 | 2023-03-07 | — | — | CN | claimed |
| US-7824899-B2 | Preparation of enantiomerically enriched amines and amides by enzymatic resolution using a sulfonylacetic acid ester as acyl donor | EVONIK DEGUSSA GMBH (DE) | 2010-11-02 | — | — | US | claimed |
| EP-1870475-B1 | Process for the preparation of optically active amines and amides employing a hydrolase and sulfonyl acetic acid ester as the acyl donor | EVONIK DEGUSSA GMBH (DE) | 2008-12-10 | — | — | EP | claimed |
| US-20070298471-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED AMINES AND AMIDES BY ENZYMATIC RESOLUTION | DEGUSSA GMBH (DE) | 2007-12-27 | — | — | US | claimed |
| EP-1870475-A1 | Process for the preparation of optically active amines and amides employing a hydrolase and sulfonyl acetic acid ester as the acyl donor | Evonik Degussa GmbH (DE) | 2007-12-26 | — | — | EP | claimed |
| US-20250129047-A1 | ISOQUINOLINE DERIVATIVES AS MUTANT EGFR MODULATORS AND USES THEREOF | NEWAVE PHARMACEUTICAL INC (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4541830-A1 | PROCESS FOR PRODUCING POLYURETHANE FOAM | Covestro Deutschland AG (DE) | 2025-04-23 | — | — | EP | disclosed |
| CN-118562037-A | Reactive water-soluble polymer, adhesive and application | 上海佰奥聚新材料科技有限公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-118026898-A | Polysubstituted cyclopropane derivative and preparation method thereof | 西安交通大学 | 2024-05-14 | — | — | CN | disclosed |
| WO-2023149431-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND POWER STORAGE DEVICE USING SAME | ＭＵアイオニックソリューションズ株式会社 | 2023-08-10 | — | — | WO | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-4227013-A | Process for preparing polyfunctional compounds | POLAROID CORPORATION (US) | 1980-10-07 | — | — | US | disclosed |
| US-4155908-A | PSORIASIS, ANTICOAGULANTS | MERCK & CO., INC. (US) | 1979-05-22 | — | — | US | disclosed |
| US-4128564-A | 9-Thia- and oxothia- and 9-dioxothia-11,12-seco-prostaglandins | MERCK & CO., INC. (US) | 1978-12-05 | — | — | US | disclosed |
| US-4127574-A | ANTIALLERGENS | SANDOZ, INC. (US) | 1978-11-28 | — | — | US | disclosed |
| US-4085125-A | 9-Thia-, 9-oxothia-, and 9-dioxothia-11,12-seco-prostaglandins and processes | MERCK & CO., INC. (US) | 1978-04-18 | — | — | US | disclosed |
| US-4066675-A | PSORIASIS, THROMBOSIS | MERCK & CO., INC. (US) | 1978-01-03 | — | — | US | disclosed |
| US-4018802-A | SKIN DISEASES, GROWTH HORMONE STIMULANTS, THROMBUS PREVENTION, IMMUNOLOGY | MERCK & CO., INC. (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129047-A1 | ISOQUINOLINE DERIVATIVES AS MUTANT EGFR MODULATORS AND USES THEREOF | EGFR, ERBB2, ERBB4 | GAA 4336/4885MGAM 4252/4885SI 4638/4885 |
| US-11661403-B2 | Oxadiazole compounds | YAP1, TEAD2, TEAD3 | GAA 3514/4885MGAM 4707/4885SI 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.